113 related articles for article (PubMed ID: 29466824)
1. QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients.
Hefner G; Hahn M; Hohner M; Roll SC; Klimke A; Hiemke C
Pharmacopsychiatry; 2019 Jan; 52(1):38-43. PubMed ID: 29466824
[TBL] [Abstract][Full Text] [Related]
2. Increase of Heart Rate and QTc by Amitriptyline, But Not by Venlafaxine, Is Correlated to Serum Concentration.
Unterecker S; Pfuhlmann B; Kopf J; Kittel-Schneider S; Reif A; Deckert J
J Clin Psychopharmacol; 2015 Aug; 35(4):460-3. PubMed ID: 26035054
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine induced QTc interval prolongation in a therapeutic dose.
Bavle A
Asian J Psychiatr; 2015 Aug; 16():63-4. PubMed ID: 26187237
[TBL] [Abstract][Full Text] [Related]
4. Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval.
Funai Y; Funao T; Ikenaga K; Takahashi R; Hase I; Nishikawa K
Osaka City Med J; 2014 Jun; 60(1):11-9. PubMed ID: 25272563
[TBL] [Abstract][Full Text] [Related]
5. Nortriptyline serum concentration as a predictor for cardiac risk in amitriptyline-treated patients.
Scherf-Clavel M; Zebner J; Hommers L; Deckert J; Menke A; Unterecker S
Eur J Clin Pharmacol; 2020 Jan; 76(1):73-80. PubMed ID: 31641787
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults.
Behlke LM; Lenze EJ; Pham V; Miller JP; Smith TW; Saade Y; Karp JF; Reynolds CF; Blumberger DM; Stefan C; Mulsant BH
J Clin Psychopharmacol; 2020; 40(6):553-559. PubMed ID: 33044352
[TBL] [Abstract][Full Text] [Related]
7. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.
Mease PJ; Zimetbaum PJ; Duh MS; Vekeman F; Guérin A; Boerstoel-Streefland M; Jiang W; Lefebvre P
Ann Pharmacother; 2011 Feb; 45(2):179-88. PubMed ID: 21304035
[TBL] [Abstract][Full Text] [Related]
8. Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2.
Scherf-Clavel M; Samanski L; Hommers LG; Deckert J; Menke A; Unterecker S
Int Clin Psychopharmacol; 2019 Mar; 34(2):93-100. PubMed ID: 30557209
[TBL] [Abstract][Full Text] [Related]
9. Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation.
Hefner G; Shams ME; Unterecker S; Falter T; Hiemke C
Pharmacopsychiatry; 2015 Sep; 48(6):215-8. PubMed ID: 26335759
[TBL] [Abstract][Full Text] [Related]
10. Risk of QT/QTc prolongation among newer non-SSRI antidepressants.
Jasiak NM; Bostwick JR
Ann Pharmacother; 2014 Dec; 48(12):1620-8. PubMed ID: 25204465
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study.
Ramzy EA
Pain Pract; 2017 Jan; 17(1):32-40. PubMed ID: 26892006
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine and takotsubo syndrome: Can we learn more from published patient cases?
Madias JE
Int J Cardiol; 2016 Dec; 225():73-74. PubMed ID: 27716552
[No Abstract] [Full Text] [Related]
13. Risk factors for QT prolongation associated with acute psychotropic drug overdose.
Miura N; Saito T; Taira T; Umebachi R; Inokuchi S
Am J Emerg Med; 2015 Feb; 33(2):142-9. PubMed ID: 25445869
[TBL] [Abstract][Full Text] [Related]
14. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse.
Rao ML; Deister A; Laux G; Staberock U; Höflich G; Möller HJ
Pharmacopsychiatry; 1996 May; 29(3):97-102. PubMed ID: 8738313
[TBL] [Abstract][Full Text] [Related]
15. [Serious QT interval prolongation associated with velafaxine administration].
Rubio Álvaro N; Tejedor Prado P; Hidalgo Correas FJ; García Diaz B
Farm Hosp; 2014 Sep; 38(5):445-6. PubMed ID: 25344139
[No Abstract] [Full Text] [Related]
16. Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients.
Ebert K; Maurice E; Lukačin R; Fleischhaker C; Schulz E; Ebert D; Clement HW
Ther Drug Monit; 2018 Jun; 40(3):351-355. PubMed ID: 29746434
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic correlates of venlafaxine: associated adverse reactions.
Schoretsanitis G; Haen E; Hiemke C; Endres K; Ridders F; Veselinovic T; Gründer G; Paulzen M
Eur Arch Psychiatry Clin Neurosci; 2019 Oct; 269(7):851-857. PubMed ID: 30923938
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic drugs associated with corrected QT interval prolongation.
van Noord C; Straus SM; Sturkenboom MC; Hofman A; Aarnoudse AJ; Bagnardi V; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
J Clin Psychopharmacol; 2009 Feb; 29(1):9-15. PubMed ID: 19142100
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships.
Hansen MR; Kuhlmann IB; Pottegård A; Damkier P
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):298-302. PubMed ID: 28397349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
